tafasitamab (Minjuvi)

following a full submission assessed under the end of life and orphan equivalent medicine process:

tafasitamab (Minjuvi®) is not recommended for use within NHSScotland.

Indication Under Review: in combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

In an open-label, uncontrolled, phase II study in patients with relapsed or refractory DLBCL who were ineligible for ASCT, tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy was associated with an objective response rate of 60%.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.